Streetbeat News

BCDA

BioCardia, Inc.

https://www.biocardia.com

Industry

Biotechnology

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Open

2.35

Mkt cap

7.9M

Volume

83K

High

2.38

P/E Ratio

-0.43

52-wk high

23.25

Low

2.25

Div yield

N/A

52-wk low

1.96

BioCardia (NASDAQ:BCDA) reported Q4 earnings with an EPS of $-0.09, beating estimates by 18.0% but with a revenue decrease of $93 thousand from the previous year. The company's past earnings performance shows mixed results with a notable share price drop of 6.0% after missing EPS estimates last quarter.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 8:10 pm

BioCardia (NASDAQ:BCDA) reported Q4 earnings with a per-share loss of $(0.09), beating the $(0.11) estimate, marking an 18.18% improvement. However, their quarterly sales of $13.00K fell short of the $90.00K estimate by 85.56%, representing an 87.74% decrease from the previous year.

Portfolio Pulse from dijoy@benzinga.com

March 27, 2024 | 8:06 pm

BioCardia, a biotechnology company, reported ending the year 2023 with cash and cash equivalents totaling $1.1 million. This financial update provides insight into the company's liquidity and financial health as of the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 6:04 pm

Earnings reports for March 27, 2024, include a mix of projected losses and earnings across various sectors. Notable companies like Cintas and Lands' End are expected to report earnings, while others like Local Bounti and REE Automotive anticipate losses. The diversity of industries, from biotechnology to retail, highlights the varied financial health within the market.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 9:02 am

BioCardia (NASDAQ:BCDA) is scheduled to release its quarterly earnings report on March 27, 2024, with an estimated EPS of $-0.11. Investors are looking for an earnings beat and positive guidance for the next quarter. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's miss leading to a 5.75% drop. Currently, BioCardia's shares are trading at $0.405, marking an 80.07% decline over the last 52 weeks, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:01 pm

BioCardia has entered into a long-term partnership with StemCardia to advance the latter's investigational pluripotent stem cell product candidate for treating heart failure. BioCardia will be the exclusive biotherapeutic delivery partner throughout the FDA approval process for an investigational new drug application (IND) and the expected Phase I/II clinical trials.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:14 am

BioCardia's stock price increased following the announcement that the Centers for Medicare & Medicaid Services (CMS) approved reimbursement coverage for its CardiAMP cell therapy Phase III heart failure study.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:06 am

BioCardia has received CMS approval for coverage of its CardiAMP Cell Therapy Phase III study in heart failure, potentially accelerating patient enrollment and advancing the therapy's development.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:04 am

U.S. stocks traded lower with the S&P 500, Dow, and NASDAQ all seeing declines. Super Micro Computer, Inc. (SMCI) is set to join the S&P 500, replacing Zions Bancorporation (ZION). Cardiff Oncology, Inc. (CRDF), Quoin Pharmaceuticals, Ltd. (QNRX), and Renalytix Plc (RNLX) saw their shares rise due to positive company developments. Conversely, BioVie Inc. (BIVI), BioCardia, Inc. (BCDA), and JOANN Inc. (JOAN) experienced significant drops in their share prices. Crude oil prices fell by 1.5%, while gold and silver prices increased.

Portfolio Pulse from Avi Kapoor

March 04, 2024 | 7:34 pm

Bitdeer Technologies Group's shares surged 10.2% after reporting positive Q4 financial results and successful testing of its Bitcoin mining chip, amidst a general rise in Bitcoin prices. Other stocks also saw significant movements, with BitFuFu Inc. leading with a 107% jump following its Nasdaq listing. The session also highlighted FDA approvals, strategic approaches, and financial results as key drivers for stock movements. Conversely, companies like BioVie Inc. and JOANN Inc. faced declines due to public offering pricing and bankruptcy reports, respectively.

Portfolio Pulse from Avi Kapoor

March 04, 2024 | 6:29 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.